How to Choose a Reproductive Microbiome Test in the UK

Choosing a reproductive microbiome test depends on your situation. The correct test for recurrent BV may not be the correct test for implantation difficulty, a uterine question, male-factor inflammation or an unresolved fungal pattern.

In general, I recommend tests that use at least 16S sequencing or next-generation sequencing. At present, only a small number of companies offer the combination of analytical depth, appropriate sample handling and access to sufficiently detailed data that I need for complex fertility work. Which company and method I select depends on the person, the sample and the point in the fertility timeline.

Start with the clinical question, not the company

Before choosing a kit, I want to know:

• whether the sample needs to be vaginal, uterine, urinary or seminal;
• whether the question concerns recurrent symptoms, inflammation, implantation, pregnancy loss or treatment response;
• what previous cultures, PCR tests or sequencing have already assessed;
• whether antibiotics, antifungals, probiotics or other treatment were used before sampling;
• and what decision the result needs to change.

Timing can matter. I use different testing approaches depending on the phase of the menstrual cycle, the treatment history and whether the person is preparing for natural conception, IVF or embryo transfer. A technically good test collected at the wrong point in the clinical timeline may still give us an incomplete answer.

The method must be sufficiently precise

“DNA test” is not an adequate description. I want to know whether the laboratory uses 16S sequencing, another next-generation sequencing method, a targeted PCR panel or a combination of methods.

For reproductive microbiome work, I generally want species-level information rather than a broad genus label. I also want detailed fungal analysis where it is clinically relevant. Not every test can provide useful fungal detail, yet sometimes that is one of the biggest clues in the case.

A laboratory may merge organisms that should be distinguished at species level. Another may detect something important but automatically label it contamination. Low-biomass samples create genuine analytical difficulties, but “contamination” must not become a convenient way to discard a finding without explaining the laboratory controls, the organism, the sample and the clinical context.

A polished report is not the same as useful data

The design of the report interests me far less than the underlying data. A commercial report may show attractive percentages and simplified red, amber and green categories while hiding exactly which organisms were detected, how they were grouped and what the test could not resolve.

Any generalised interpretation is an intentional simplification. As a specialist, I want to see the least filtered version available: the species-level pattern, relative abundance, relevant fungal findings, methodological limits, quality controls and any raw or extended data the laboratory can provide.

Percentages alone can also conceal the real picture. A result needs to be read as a microbial community and placed alongside symptoms, inflammatory questions, previous treatment and the reproductive timeline.

Questions to ask about the laboratory

Before using a test, establish:

• where the sample is analysed and under which quality framework;
• how the sample remains stable during collection and transport;
• whether the method has been validated for that exact sample type;
• the taxonomic resolution the laboratory can reliably provide;
• whether bacteria and fungi are both assessed in sufficient detail;
• how low-biomass samples and possible contamination are handled;
• whether species are merged or filtered before they appear in the report;
• whether the extended or less-filtered data can be reviewed;
• and whether a suitably qualified person can answer methodological questions.

What happens after the result matters most

A commercial microbiome report is not usually accepted by a GP as a medical diagnosis or as an instruction to prescribe. UK IVF clinics are increasingly familiar with these reports, but familiarity does not mean that the clinic will interpret every finding or build a treatment plan around it.

When you work with me, I interpret the result within the full fertility and health picture. Where communication with a medical professional is needed, I provide a referral letter that explains the relevant findings, the clinical context and the questions that need medical assessment. I regularly work successfully with GPs in this way.

The partner is included in every fertility investigation. A vaginal result cannot be treated as an isolated female problem when the couple shares reproductive and microbial exposures. The Male Fertility and seminal microbiome section explains why the male side needs its own assessment and testing.

The result must be mapped onto your health picture

The test is only the beginning. I then look more deeply at what may be shaping the result: gut, metabolic and hormonal health; recurrent infection; previous antimicrobial treatment; environmental history; symptoms; the partner’s findings; and the timing of fertility treatment.

The important question is not simply “What organisms were found?” It is “Why does this community look like this in this person, at this point in the cycle and fertility timeline, and what should we do next?”

Before booking, you may want to familiarise yourself with my methodology. If you are deciding between reproductive microbiome tests, or already have a report that has not been properly interpreted, you can book an Introductory Fertility Review. I will review the clinical question first and recommend the testing route that fits your situation.

This article is educational and does not replace medical advice, diagnosis or treatment. Diagnosis and any prescribed treatment should be provided by a qualified medical professional.